ERBB2 and cancer: NCT03457896: Study of Netatinib + Trastuzumab orNeratinib + Cetuximab in Patients WithKRAS/NRAS/BRAS/PIK3CA Wild-Type MetastaticColorectal Cancer by HER2 Status